Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

  • ID: 4462179
  • Report
  • 699 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size. While hormone-sensitive prostate cancer is well managed in terms of treatment options, unmet need persists for patients with prostate cancer that is no longer responsive to hormonal manipulation. Newly approved therapies for castration-resistant prostate cancer are set to create a shift in the way that the disease is treated, while creating a competitive environment for new market entrants.

Market Snapshot
  • Zytiga will face generic erosion, ensuring Xtandi remains the most valuable brand over the forecast period.
  • ADT remains the most popular treatment choice for the majority of prostate cancer patients.
  • Label expansions into earlier treatment settings will help Xtandi combat growing competition.
  • Treatment may become more segmented as pipeline drugs with new mechanisms of action reach the market.
  • Drugs targeting non-metastatic CRPC will need to engage in rebate contracting in the US and in outcome-based risk-sharing agreements in the EU.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: PROSTATE CANCER (Published on 18 January 2018)
EXECUTIVE SUMMARY
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE (LATE STAGE): DCVAC/PCA
PRODUCT PROFILE: ELIGARD
PRODUCT PROFILE: FIRMAGON
PRODUCT PROFILE: JEVTANA
PRODUCT PROFILE: LUPRON
PRODUCT PROFILE (LATE STAGE): LYNPARZA
PRODUCT PROFILE: PROVENGE
PRODUCT PROFILE (LATE STAGE): RUBRACA
PRODUCT PROFILE (LATE STAGE): TECENTRIQ
PRODUCT PROFILE: TRELSTAR
PRODUCT PROFILE: XOFIGO
PRODUCT PROFILE: XTANDI
PRODUCT PROFILE (LATE STAGE): YONSA
PRODUCT PROFILE: ZOLADEX
PRODUCT PROFILE: ZYTIGA
PRODUCT PROFILE (LATE STAGE): APALUTAMIDE
PRODUCT PROFILE (LATE STAGE): DAROLUTAMIDE
PRODUCT PROFILE (LATE STAGE): IPATASERTIB
PRODUCT PROFILE (LATE STAGE): MASITINIB
PRODUCT PROFILE (LATE STAGE): RELUGOLIX

TREATMENT: PROSTATE CANCER (Published on 20 November 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: PROSTATE CANCER (Published on 08 September 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
METHODOLOGY
FORECAST
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: PROSTATE CANCER (Published on 18 January 2018)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: ELIGARD
PRODUCT PROFILE: FIRMAGON
PRODUCT PROFILE: JEVTANA
PRODUCT PROFILE: LUPRON
PRODUCT PROFILE: PROVENGE
PRODUCT PROFILE: TRELSTAR
PRODUCT PROFILE: XOFIGO
PRODUCT PROFILE: XTANDI
PRODUCT PROFILE: ZOLADEX
PRODUCT PROFILE: ZYTIGA

PROSTATE CANCER PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 July 2016)
EXECUTIVE SUMMARY
MARKET CONTEXT
GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS
US PRICING
US PAYER AND KEY OPINION LEADER INSIGHTS
US REIMBURSEMENT
JAPAN
PRICING IN THE FIVE MAJOR EU MARKETS
FIVE MAJOR EU MARKETS PAYER AND KEY OPINION LEADER INSIGHTS
FRANCE
GERMANY
ITALY
SPAIN
UK
APPENDIX

PIPELINE: PROSTATE CANCER (Published on 18 January 2018)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
CLINICAL TRIAL DESIGN
RECENTLY DISCONTINUED DRUGS
PRODUCT PROFILE (LATE STAGE): DCVAC/PCA
PRODUCT PROFILE (LATE STAGE): LYNPARZA
PRODUCT PROFILE (LATE STAGE): RUBRACA
PRODUCT PROFILE (LATE STAGE): TECENTRIQ
PRODUCT PROFILE (LATE STAGE): YONSA
PRODUCT PROFILE (LATE STAGE): APALUTAMIDE
PRODUCT PROFILE (LATE STAGE): DAROLUTAMIDE
PRODUCT PROFILE (LATE STAGE): IPATASERTIB
PRODUCT PROFILE (LATE STAGE): MASITINIB
PRODUCT PROFILE (LATE STAGE): RELUGOLIX

List of Figures
Figure 1: Prostate cancer - current and future market dynamics analysis
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for prostate cancer
Figure 3: Prostate cancer sales across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Prostate cancer sales across the US, Japan, and five major EU markets, by class, 2017-26
Figure 5: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 6: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 7: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 8: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 9: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 10: Patient-based forecast methodology for prostate cancer
Figure 11: Price sources and calculations, by country
Figure 12: DCVAC/PCa for prostate cancer - SWOT analysis
Figure 13: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 14: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 15: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 16: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 17: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 18: Jevtana for prostate cancer - SWOT analysis
Figure 19: Drug assessment summary of Jevtana for prostate cancer
Figure 20: Drug assessment summary of Jevtana for prostate cancer
Figure 21: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 22: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 23: Lynparza for prostate cancer - SWOT analysis
Figure 24: Drug assessment summary of Lynparza for prostate cancer
Figure 25: Drug assessment summary of Lynparza for prostate cancer
Figure 26: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 27: Provenge for prostate cancer - SWOT analysis
Figure 28: Drug assessment summary of Provenge for prostate cancer
Figure 29: Drug assessment summary of Provenge for prostate cancer
Figure 30: Provenge sales for prostate cancer in the US, 2017-26
Figure 31: Rubraca for prostate cancer - SWOT analysis
Figure 32: Drug assessment summary of Rubraca for prostate cancer
Figure 33: Drug assessment summary of Rubraca for prostate cancer
Figure 34: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017-26
Figure 35: Tecentriq for prostate cancer - SWOT analysis
Figure 36: Drug assessment summary of Tecentriq for prostate cancer
Figure 37: Drug assessment summary of Tecentriq for prostate cancer
Figure 38: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 39: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017-26
Figure 40: Xofigo for prostate cancer - SWOT analysis
Figure 41: Drug assessment summary of Xofigo for prostate cancer
Figure 42: Drug assessment summary of Xofigo for prostate cancer
Figure 43: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 44: Xtandi for prostate cancer - SWOT analysis
Figure 45: Drug assessment summary of Xtandi for prostate cancer
Figure 46: Drug assessment summary of Xtandi for prostate cancer
Figure 47: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 48: Yonsa for prostate cancer - SWOT analysis
Figure 49: Drug assessment summary of Yonsa for prostate cancer
Figure 50: Drug assessment summary of Yonsa for prostate cancer
Figure 51: Yonsa sales for prostate cancer in the US, 2017-26
Figure 52: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 53: Zytiga for prostate cancer - SWOT analysis
Figure 54: Drug assessment summary of Zytiga for prostate cancer
Figure 55: Drug assessment summary of Zytiga for prostate cancer
Figure 56: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 57: Apalutamide for prostate cancer - SWOT analysis
Figure 58: Drug assessment summary of apalutamide for prostate cancer
Figure 59: Drug assessment summary of apalutamide for prostate cancer
Figure 60: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 61: Darolutamide for prostate cancer - SWOT analysis
Figure 62: Drug assessment summary of darolutamide for prostate cancer
Figure 63: Drug assessment summary of darolutamide for prostate cancer
Figure 64: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 65: Ipatasertib for prostate cancer - SWOT analysis
Figure 66: Drug assessment summary of ipatasertib for prostate cancer
Figure 67: Drug assessment summary of ipatasertib for prostate cancer
Figure 68: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 69: Masitinib for prostate cancer - SWOT analysis
Figure 70: Drug assessment summary of masitinib for prostate cancer
Figure 71: Drug assessment summary of masitinib for prostate cancer
Figure 72: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
Figure 73: Relugolix for prostate cancer - SWOT analysis
Figure 74: Drug assessment summary of relugolix for prostate cancer
Figure 75: Drug assessment summary of relugolix for prostate cancer
Figure 76: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 77: Localized prostate cancer patients receiving each type of treatment, by country
Figure 78: Localized prostate cancer patients treated with pharmacological therapy + prostatectomy receiving neoadjuvant and/or adjuvant therapy
Figure 79: Localized prostate cancer patients treated with pharmacological therapy + radiotherapy receiving neoadjuvant, concurrent, and/or adjuvant therapy
Figure 80: Pharmacologically treated localized prostate cancer patients receiving each therapy type, by country
Figure 81: Top three regimens used in localized prostate cancer patients treated with ADT, by country
Figure 82: Locally advanced prostate cancer patients receiving each type of treatment, by country
Figure 83: Pharmacologically treated locally advanced prostate cancer patients receiving each therapy type, by country
Figure 84: Top three regimens used in locally advanced prostate cancer patients treated with ADT, by country
Figure 85: Metastatic castration-naïve prostate cancer patients receiving each type of treatment, by country
Figure 86: Pharmacologically treated metastatic castration-naïve prostate cancer patients receiving each therapy type, by country
Figure 87: Top three regimens used in metastatic castration-naïve prostate cancer patients treated with ADT, by country
Figure 88: Recurrent/progressive prostate cancer patients receiving each type of treatment at first line, by country
Figure 89: Recurrent/progressive prostate cancer patients receiving each type of treatment at second line, by country
Figure 90: Pharmacologically treated recurrent/progressive prostate cancer patients receiving each therapy type at first and second line
Figure 91: Top three first-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
Figure 92: Top three second-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
Figure 93: nmCRPC patients receiving each type of treatment at first line, by country
Figure 94: nmCRPC patients receiving each type of treatment at second line, by country
Figure 95: Pharmacologically treated nmCRPC patients receiving each therapy type at first line and second line
Figure 96: Top three first-line regimens for nmCRPC patients treated with ADT, by country
Figure 97: Top three second-line regimens for nmCRPC patients treated with ADT, by country
Figure 98: Top three first-line regimens for nmCRPC patients treated with chemotherapy, by country
Figure 99: Top three second-line regimens for nmCRPC patients treated with chemotherapy, by country
Figure 100: mCRPC patients receiving each type of treatment at first line, by country
Figure 101: mCRPC patients receiving each type of treatment at second line, by country
Figure 102: mCRPC patients receiving each type of treatment at third line, by country
Figure 103: Pharmacologically treated mCRPC patients receiving each therapy type at first line, second line, and third line
Figure 104: Top three first-line regimens for mCRPC patients treated with ADT, by country
Figure 105: Top three second-line regimens for mCRPC patients treated with ADT, by country
Figure 106: Top three third-line regimens for mCRPC patients treated with ADT, by country
Figure 107: Top three first-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 108: Top three second-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 109: Top three third-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 110: Top three first-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 111: Top three second-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 112: Top three third-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 113: Trends in incident cases of diagnosed prostate cancer in the US, Japan, and five major EU markets, 2014-34
Figure 114: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 115: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 116: Jevtana for prostate cancer - SWOT analysis
Figure 117: Drug assessment summary of Jevtana for prostate cancer
Figure 118: Drug assessment summary of Jevtana for prostate cancer
Figure 119: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 120: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 121: Provenge for prostate cancer - SWOT analysis
Figure 122: Drug assessment summary of Provenge for prostate cancer
Figure 123: Drug assessment summary of Provenge for prostate cancer
Figure 124: Provenge sales for prostate cancer in the US, 2017-26
Figure 125: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017-26
Figure 126: Xofigo for prostate cancer - SWOT analysis
Figure 127: Drug assessment summary of Xofigo for prostate cancer
Figure 128: Drug assessment summary of Xofigo for prostate cancer
Figure 129: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 130: Xtandi for prostate cancer - SWOT analysis
Figure 131: Drug assessment summary of Xtandi for prostate cancer
Figure 132: Drug assessment summary of Xtandi for prostate cancer
Figure 133: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 134: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 135: Zytiga for prostate cancer - SWOT analysis
Figure 136: Drug assessment summary of Zytiga for prostate cancer
Figure 137: Drug assessment summary of Zytiga for prostate cancer
Figure 138: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 139: Use of Xtandi and Zytiga among non-ADT pharmacological therapies in chemotherapy-naïve mCRPC patients (% of patients), by country
Figure 140: DCVAC/PCa for prostate cancer - SWOT analysis
Figure 141: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 142: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 143: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 144: Lynparza for prostate cancer - SWOT analysis
Figure 145: Drug assessment summary of Lynparza for prostate cancer
Figure 146: Drug assessment summary of Lynparza for prostate cancer
Figure 147: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 148: Rubraca for prostate cancer - SWOT analysis
Figure 149: Drug assessment summary of Rubraca for prostate cancer
Figure 150: Drug assessment summary of Rubraca for prostate cancer
Figure 151: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017-26
Figure 152: Tecentriq for prostate cancer - SWOT analysis
Figure 153: Drug assessment summary of Tecentriq for prostate cancer
Figure 154: Drug assessment summary of Tecentriq for prostate cancer
Figure 155: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 156: Yonsa for prostate cancer - SWOT analysis
Figure 157: Drug assessment summary of Yonsa for prostate cancer
Figure 158: Drug assessment summary of Yonsa for prostate cancer
Figure 159: Yonsa sales for prostate cancer in the US, 2017-26
Figure 160: Apalutamide for prostate cancer - SWOT analysis
Figure 161: Drug assessment summary of apalutamide for prostate cancer
Figure 162: Drug assessment summary of apalutamide for prostate cancer
Figure 163: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 164: Darolutamide for prostate cancer - SWOT analysis
Figure 165: Drug assessment summary of darolutamide for prostate cancer
Figure 166: Drug assessment summary of darolutamide for prostate cancer
Figure 167: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 168: Ipatasertib for prostate cancer - SWOT analysis
Figure 169: Drug assessment summary of ipatasertib for prostate cancer
Figure 170: Drug assessment summary of ipatasertib for prostate cancer
Figure 171: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 172: Masitinib for prostate cancer - SWOT analysis
Figure 173: Drug assessment summary of masitinib for prostate cancer
Figure 174: Drug assessment summary of masitinib for prostate cancer
Figure 175: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
Figure 176: Relugolix for prostate cancer - SWOT analysis
Figure 177: Drug assessment summary of relugolix for prostate cancer
Figure 178: Drug assessment summary of relugolix for prostate cancer
Figure 179: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Prostate cancer sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 2: Prostate cancer sales across the US, Japan, and five major EU markets, by class ($m), 2017-26
Table 3: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
Table 4: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
Table 6: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 7: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
Table 8: Summary of drug classes and molecules included in the author’s prostate cancer patient-based forecast
Table 9: Exchange rates used for calculating prices
Table 10: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
Table 11: DCVAC/PCa drug profile
Table 12: DCVAC/PCa Phase III trial in prostate cancer
Table 13: DCVAC/PCa Phase I/II data in prostate cancer
Table 14: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 15: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 16: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 17: Jevtana drug profile
Table 18: Jevtana pivotal Phase III data in prostate cancer
Table 19: Jevtana Phase III data in prostate cancer
Table 20: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 21: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 22: Lynparza drug profile
Table 23: Lynparza Phase III trial in prostate cancer
Table 24: Lynparza Phase II data in prostate cancer
Table 25: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 26: Provenge drug profile
Table 27: Provenge pivotal Phase III data in prostate cancer
Table 28: Provenge sales for prostate cancer in the US ($m), 2017-26
Table 29: Rubraca drug profile
Table 30: Rubraca trials in prostate cancer
Table 31: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
Table 32: Tecentriq drug profile
Table 33: Tecentriq Phase III trials in prostate cancer
Table 34: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 35: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
Table 36: Xofigo drug profile
Table 37: Xofigo Phase III data in prostate cancer
Table 38: Xofigo Phase III trials in prostate cancer
Table 39: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 40: Xtandi drug profile
Table 41: Xtandi Phase III data in prostate cancer
Table 42: Xtandi Phase III trials in prostate cancer
Table 43: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 44: Yonsa drug profile
Table 45: Yonsa Phase II/III trial in prostate cancer
Table 46: Yonsa sales for prostate cancer in the US ($m), 2017-26
Table 47: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 48: Zytiga drug profile
Table 49: Zytiga Phase III data in prostate cancer
Table 50: Zytiga Phase III trials in prostate cancer
Table 51: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 52: Apalutamide drug profile
Table 53: Apalutamide Phase III data in prostate cancer
Table 54: Apalutamide Phase I/II data in prostate cancer
Table 55: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 56: Darolutamide drug profile
Table 57: Darolutamide Phase III trials in prostate cancer
Table 58: Darolutamide Phase I/II data in prostate cancer
Table 59: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 60: Ipatasertib drug profile
Table 61: Ipatasertib Phase III trial in prostate cancer
Table 62: Ipatasertib Phase II data in prostate cancer
Table 63: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 64: Masitinib drug profile
Table 65: Masitinib Phase III trial in prostate cancer
Table 66: Masitinib Phase II data in prostate cancer
Table 67: Masitinib sales for prostate cancer across the five major EU markets, by country ($m), 2017-26
Table 68: Relugolix drug profile
Table 69: Relugolix Phase III trials in prostate cancer
Table 70: Relugolix Phase II data in prostate cancer
Table 71: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 72: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
Table 73: Percentage of US males who will develop prostate cancer over 10-, 20-, and 30-year intervals according to their current age, 2010-12
Table 74: Prostate cancer five-year relative survival rates in the US, by stage at diagnosis
Table 75: NCCN prostate cancer patient segmentation, by risk group
Table 76: ESMO prostate cancer patient segmentation, by risk group
Table 77: Prostate cancer segmentation using TNM stage, risk group, PSA measurement, and Gleason score
Table 78: Prostate cancer segmentation by clinical state
Table 79: Leading treatments for prostate cancer
Table 80: Cancer registry databases used as a source of prostate cancer incidence data, by country
Table 81: Forecasting methodology for prostate cancer incidence, by country, age group, and gender
Table 82: Sources of survival data used to estimate prostate cancer prevalence, by country
Table 83: Incident cases of prostate cancer in the US, Japan, and five major EU markets, by country, 2016-36
Table 84: Profiled key marketed drugs for prostate cancer
Table 85: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 86: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 87: Jevtana drug profile
Table 88: Jevtana pivotal Phase III data in prostate cancer
Table 89: Jevtana Phase III data in prostate cancer
Table 90: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 91: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 92: Provenge drug profile
Table 93: Provenge pivotal Phase III data in prostate cancer
Table 94: Provenge sales for prostate cancer in the US ($m), 2017-26
Table 95: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
Table 96: Xofigo drug profile
Table 97: Xofigo Phase III data in prostate cancer
Table 98: Xofigo Phase III trials in prostate cancer
Table 99: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 100: Xtandi drug profile
Table 101: Xtandi Phase III data in prostate cancer
Table 102: Xtandi Phase III trials in prostate cancer
Table 103: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 104: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 105: Zytiga drug profile
Table 106: Zytiga Phase III data in prostate cancer
Table 107: Zytiga Phase III trials in prostate cancer
Table 108: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 109: Marketed prostate cancer products and approved indications in the US, Japan, and five major EU markets
Table 110: Late-stage candidates in development for prostate cancer
Table 111: Levers impacting access to prostate cancer drugs in the US and five major EU markets
Table 112: Phase III pivotal studies in non-metastatic CRPC
Table 113: Phase III trials in metastatic hormone-sensitive prostate cancer
Table 114: Studies of docetaxel in metastatic hormone-sensitive prostate cancer
Table 115: US pricing of marketed prostate cancer drugs
Table 116: Prostate cancer clinical pathway used by Anthem’s Cancer Care Quality Program
Table 117: Formulary placement of prostate cancer drugs in selected commercial formularies
Table 118: Formulary placement of prostate cancer drugs in top four Medicare Part D formularies
Table 119: Pivotal trial data for Xtandi and Zytiga in chemotherapy-naïve mCRPC
Table 120: Prior authorization criteria for Jevtana, Provenge, Xofigo, Xtandi, and Zytiga in four major health plans
Table 121: Pricing premiums given to medicines that can demonstrate benefit over comparators
Table 122: Pricing of key marketed prostate cancer drugs in Japan
Table 123: Price calculation methodologies for prostate cancer drugs in Japan launched after 2008
Table 124: Pricing of key prostate cancer drugs in the five major EU markets
Table 125: Transparency Committee's ASMR ratings and pricing implications
Table 126: Transparency Committee's SMR ratings and pricing implications
Table 127: Transparency Committee's assessment of prostate cancer treatments
Table 128: G-BA assessment of key prostate cancer therapies
Table 129: Classification of a new drug submission according to NUB status
Table 130: Reimbursement conditions for prostate cancer drugs in Italy
Table 131: Prostate cancer drug assessments by the Emilia-Romagna region
Table 132: Prostate cancer drug assessments by the Veneto region
Table 133: Comparing the Emilio-Romagna region to the Veneto region
Table 134: Spanish national and regional health reimbursement decisions for prostate cancer drugs
Table 135: Spanish Oncology Genitourinary Group recommendations for mCRPC
Table 136: NICE assessments of key prostate cancer therapies
Table 137: SMC decisions on key prostate cancer therapies
Table 138: Price sources and calculations, by country
Table 139: Exchange rates used for calculating prices
Table 140: Profiled pipeline products in development for prostate cancer
Table 141: Typical Phase III clinical trial design in prostate cancer
Table 142: Late-stage compound that was recently discontinued for prostate cancer
Table 143: DCVAC/PCa drug profile
Table 144: DCVAC/PCa Phase III trial in prostate cancer
Table 145: DCVAC/PCa Phase I/II data in prostate cancer
Table 146: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 147: Lynparza drug profile
Table 148: Lynparza Phase III trial in prostate cancer
Table 149: Lynparza Phase II data in prostate cancer
Table 150: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 151: Rubraca drug profile
Table 152: Rubraca trials in prostate cancer
Table 153: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
Table 154: Tecentriq drug profile
Table 155: Tecentriq Phase III trials in prostate cancer
Table 156: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll